Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 as Monotherapy for Advanced Pancreatic Cancer
January 16, 2025 | 07:03
Innovent Biologics, Inc., announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for IBI343.
Innovent Announces Second New Drug Application of DOVBLERON was Approved by China's National Medical Products Administration
January 03, 2025 | 07:00
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases.
Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate
January 02, 2025 | 06:30
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases.
Innovent to Present Clinical Data of Multiple Novel Molecules at ESMO Asia 2024
November 25, 2024 | 07:30
Innovent Biologics, Inc.,announces that nearly 10 accepted clinical data of its novel oncology molecules
Mobile Version